Focus: Black Diamond Therapeutics is a Cambridge-based biotech company focused on discovering and developing allosteric mutant oncogene inhibitors for precision oncology. The company operates as a publicly traded mid-cap biotech with a lean pipeline targeting high-value oncology indications.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Black Diamond Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Black Diamond Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Black Diamond Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Black Diamond Therapeutics Inc (BDTX-Q) Stock Price and News - The Globe and Mail
Black Diamond Therapeutics Inc (BDTX-Q) Stock Price and News The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR) The Globe and Mail
Black Diamond Therapeutics (BDTX) director opts for 6,801 shares instead of cash - Stock Titan
Black Diamond Therapeutics (BDTX) director opts for 6,801 shares instead of cash Stock Titan
Black Diamond (NASDAQ: BDTX) director takes stock in lieu of cash fees - Stock Titan
Black Diamond (NASDAQ: BDTX) director takes stock in lieu of cash fees Stock Titan
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference GlobeNewswire
Black Diamond Therapeutics (BDTX) Dips 1.76% as Shares Test Key Support Zone - MFI Overbought - dars.gov.et
Black Diamond Therapeutics (BDTX) Dips 1.76% as Shares Test Key Support Zone - MFI Overbought dars.gov.et
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications